一名患者在诊断前列腺癌时患有广泛强烈的前列腺特异性膜抗原表达、BRCA 基因突变阳性骨转移，在接受多种标准治疗后病情进展。他接受了 177Lu 前列腺特异性膜抗原 8.5 GBq 治疗，并辅以短疗程的奥拉帕尼放射增敏治疗，单次治疗后血清 PSA 水平降低了 90%。他的肿瘤反应比预测剂量测定预期的要好得多。然而，他的骨髓放射毒性比预期严重，需要住院治疗。这表明放射增敏剂是一把双刃剑，在活动处方期间必须仔细考虑和平衡。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

A patient with widespread intensely prostate-specific membrane antigen-expressing, BRCA gene mutation-positive bone metastases at the time of prostate cancer diagnosis had progressed on multiple lines of standard therapy. He received 177Lu-prostate-specific membrane antigen 8.5 GBq augmented by a short course of olaparib radiosensitization and achieved 90% decrease in serum PSA level after a single treatment. His tumor response was much better than expected by predictive dosimetry. However, his marrow radiotoxicity was worse than anticipated and required hospitalization. This suggests radiosensitizing agents to be a double-edged sword that must be carefully considered and balanced during activity prescription.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.